Ornique (Ethinylestradiol, Etonogestrel)

Ethinylestradiol/Etonogestrel, the active ingredient in Ornique, is a combined estrogen‑progestogen contraceptive presented as a vaginal ring for vaginal use. It prevents pregnancy in women of reproductive age. GNH USA supplies Ornique as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ornique is a combined hormonal contraceptive that acts on the reproductive endocrine system to prevent unintended pregnancy. - Contraception: prevents pregnancy by inhibiting ovulation and altering cervical mucus. - Menstrual cycle regulation: helps achieve more predictable monthly bleeding patterns. - Acne management: reduces androgen‑driven skin lesions in women seeking hormonal control.

Ornique may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often resolves with continued use. - Breast tenderness: transient discomfort. - Vaginal irritation: mild irritation at the ring site. - Spotting: irregular bleeding during initial cycles. - Mood changes: mild emotional fluctuations.

Serious or Rare Side Effects: - Deep vein thrombosis: rare clot formation in veins. - Pulmonary embolism: rare blockage of lung arteries. - Hepatic adenoma: uncommon liver tumor. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hypertension: elevated blood pressure in susceptible individuals.

Before prescribing Ornique, clinicians should assess individual risk factors and contraindications. - Smoking status: avoid in women over 35 who smoke heavily. - Cardiovascular disease: contraindicated in patients with history of thromboembolic events. - Liver disease: caution in severe hepatic impairment. - Migraine with aura: avoid due to increased stroke risk. - Breast cancer: contraindicated in active or past breast malignancy. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ornique can interact with several medicines that affect hormone metabolism or clotting risk.

Major Interactions (Avoid): - Anticoagulants: may reduce effectiveness of warfarin. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower hormone levels, decreasing contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antiepileptics (e.g., phenytoin): may modestly reduce hormone concentrations. - Antifungals (e.g., ketoconazole): may increase hormone levels, raising side‑effect risk. - Herbal supplements (e.g., St. John’s Wort): may modestly reduce efficacy.